NCT06419101 · RECRUITING
Exploring the Diagnostic Biomarkers of Cognitive Disorders in China
This study is building a large database of Chinese patients with memory complaints, tracking them over time to find biomarkers that could help detect dementia earlier. Researchers will collect cognitive tests, brain imaging, and blood samples to watch how things change. There is no assigned treatment. This is an observational cohort study, not a clinical trial testing a drug or therapy, so there is no phase designation.
You may qualify if
- Male or female patients aged ≥40 and ≤90years;
- Chief complaint or others describe a cognitive decline;
- Ability to communicate in Chinese;
- The patients and their families were informed and signed the informed consent.
You're excluded if
- MMSE\<10;
- There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);
- There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
- Suffering from a disease that cannot cooperate with the completion of cognitive examination;
- There are contraindications to nuclear magnetic resonance;
- There is mental and neurodevelopmental delay;
- Refuse to draw blood;
- Refuse to sign the informed consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-11-14